Management of attention-deficit hyperactivity disorder in adults: Focus on methylphenidate hydrochloride

Neuropsychiatric Disease and Treatment

Volumn 5, Issue 1, 2009, Pages 421-432

  Nair, Rajasree ^a   Moss, Shannon B ^a  

^a Baylor Family Medicine Residency at Garland   (United States)

Author keywords

Adult ADHD; Methylphenidate hydrochloride; Stimulants; Treatment

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE; AMPHETAMINE DERIVATIVE; ANTIDEPRESSANT AGENT; ATOMOXETINE; CLONIDINE; DESIPRAMINE; DEXAMPHETAMINE; DEXMETHYLPHENIDATE; IMIPRAMINE; LISDEXAMFETAMINE; LONG ACTING DRUG; METHYLPHENIDATE; MODAFINIL; NORTRIPTYLINE; PEMOLINE; PLACEBO; PSYCHOSTIMULANT AGENT; SHORT ACTING DRUG; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL PAIN; ADJUVANT THERAPY; ADRENERGIC SYSTEM; ANOREXIA; APPETITE DISORDER; ATTENTION DEFICIT DISORDER; BLOOD BRAIN BARRIER; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COGNITIVE THERAPY; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DECREASED APPETITE; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DOPAMINERGIC SYSTEM; DOSAGE SCHEDULE COMPARISON; DRUG ABSORPTION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG COST; DRUG DEPENDENCE; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG MECHANISM; DRUG MONITORING; DRUG PENETRATION; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPEPSIA; ERECTILE DYSFUNCTION; EVENING DOSAGE; EVIDENCE BASED MEDICINE; FAMILY THERAPY; HEART MUSCLE CONDUCTION DISTURBANCE; HEART PALPITATION; HUMAN; HYPERTENSION; INSOMNIA; JAUNDICE; LACTATION; LIVER TOXICITY; LOW DRUG DOSE; MOOD DISORDER; MORNING DOSAGE; NARCOLEPSY; NAUSEA; NERVOUSNESS; PREGNANCY; PSYCHOLOGIC ASSESSMENT; PSYCHOSOCIAL DISORDER; PULSE RATE; REVIEW; SIDE EFFECT; SLEEP DISORDER; TACHYCARDIA; UNSPECIFIED SIDE EFFECT; VOMITING; WEIGHT REDUCTION; XEROSTOMIA;

EID: 70449721440     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: None     Document Type: Review

References (80)

1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition. Washington, DC: American Psychiatric Association; 2000.
2. Moss SB, Nair R, Vallarino A, Wang S. Attention deficit/hyperactivity disorder in adults. Prim Care. 2007;34(3):445-473.
3. Faraone SV, Spencer TJ, Montano CB, Biederman J. Attention-deficit/ hyperactivity disorder in adults: a survey of current practice in psychiatry and primary care. Arch Intern Med. 2004;164(11):1221-1226. (Pubitemid 39030359)
4. Faraone SV, Biederman J, Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006;36:159-165. (Pubitemid 43126140)
5. Kessler RC, Adler L, Barkley R, et al. The prevalence and correlates of adult ADHD in the United States: results from the National Comorbidity Survey replication. Am J Psychiatry. 2006;163:716-723. (Pubitemid 44464584)
6. Sankaranarayanan J, Puumala SE, Kratochvil CJ. Diagnosis and treatment of adult attention-deficit/hyperactivity disorder at US ambulatory care visits from 1996 to 2003. Curr Med Res Opin. 2006;22(8):1475-1491.
7. Barkley RA, Brown TE. Unrecognized attention-deficit/hyperactivity disorder in adults presenting with other psychiatric disorders. CNS Spectr. 2008;13:977-984.
8. Searight HR, Burke JM, Rottnek F. Adult ADHD: evaluation and treatment in family medicine. Am Fam Physician. 2000;62:2077-2086.
9. McGough JJ, Barkley RA. Diagnostic controversies in adult attention deficit hyperactivity disorder. Am J Psychiatry. 2004;161:1948-1956. (Pubitemid 39441393)
10. Riccio CA, Wolfe M, Davis B, Romine C, George C, Lee D. Attention deficit hyperactivity disorder: manifestation in adulthood. Arch Clin Neuropsychol. 2005;20:249-269. (Pubitemid 40222162)
11. Mick E, Faraone SV, Biederman J. Age-dependent expression of attention-deficit/hyperactivity disorder symptoms. Psychiatr Clin N Am. 2004;27:215-224. (Pubitemid 38452764)
12. Mannuzza S, Klein RG, Klein DF, Bessler A, Shrout P. Accuracy of adult recall of childhood attention deficit hyperactivity disorder. Am J Psychiatr. 2002;159:1882-1888. (Pubitemid 35283254)
13. Roy-Byrne P, Scheele L, Brinkley J, et al. Adult attention-deficit hyperactivity disorder: assessment guidelines based on clinical presentation to a specialty clinic. Compr Psychiatry. 1997;38(3):133-140. (Pubitemid 27208956)
14. Applegate B, Lahey BB, Hart EL, et al. Validity of the age-of-onset criterion for ADHD: a report from the DSM-IV field trials. J Am Acad Child Adolesc Psychiatry. 1997;36(9):1211-1221. (Pubitemid 27381277)
15. Ward MF, Wender PH, Reimherr FW. The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry. 1993;150:885-890.
16. Wilens TE, Kwon A, Tanguay S, et al. Characteristics of adults with attention deficit hyperactivity disorder plus substance use disorder: the role of psychiatric comorbidity. Am J Addict. 2005;14:319-327. (Pubitemid 41318270)
17. Kolar D, Keller A, Golfinopoulos M, Cumyn L, Syer C, Hechtman L. Treatment of adults with attention-deficit/hyperactivity disorder. Neuropsychiatr Dis Treat. 2008;4(2):389-403.
18. Biederman J, Faraone SV, Spencer TJ, Mick E, Monuteaux MC, Aleardi M. Functional impairments in adults with self-reports of diagnosed ADHD: a controlled study of 1001 adults in the community. J Clin Psychiatry. 2006;67:524-540. (Pubitemid 43764229)
19. Barkley RA, Guevremont DC, Anastopoulos AD, DuPaul GJ, Shelton TL. Driving-related risks and outcomes of attention deficit hyperactivity disorder in adolescents and young adults: a 3- to 5-year follow-up survey. Pediatrics. 1993;92(2):212-218.
20. Wilens TE, Biederman J, Mick E, Faraone SV, Spencer T. Attention deficit hyperactivity disorder (ADHD) is associated with early onset substance use disorders. J Nerv Ment Dis. 1997;185(8):475-482. (Pubitemid 27376655)
21. Biederman J, Wilens T, Mick E, Milberger S, Spencer TJ, Faraone SV. Psychoactive substance use disorders in adults with attention deficit hyperactivity disorder (ADHD): effects of ADHD and psychiatric comorbidity. Am J Psychiatry. 1995;152(11):1652-1658.
22. Kessler RC, Adler L, Ames M, et al. The World Health Organization adult ADHD self-rep ort scale (ASRS): a short screening scale for use in the general population. Psychol Med. 2005;35:245-256. (Pubitemid 40259916)
23. Gallagher R, Blader J. The diagnosis and neuropsychological assessment of adult attention deficit/hyperactivity disorder: scientific and practical guidelines. Ann NY Acad Sci. 2001;931:148-171. (Pubitemid 32612786)
24. Asherson P. Clinical assessment and treatment of attention deficit hyperactivity disorder in adults. Expert Rev Neurotherapeutics. 2005;5(4):525-539. (Pubitemid 41021059)
25. Wasserstein J. Diagnostic issues for adolescents and adults with ADHD. J Clin Psychol. 2005;61:535-547. (Pubitemid 40776542)
26. Faraone SV, Perlis RH, Doyle AE, et al. Molecular genetics of attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57(11):1313- 1323.
27. Adler L, Spencer T, Faraone SV, et al. Validity of pilot Adult ADHD Self-Report Scale (ASRS) to rate adult ADHD symptoms. Ann Clin Psychiatry. 2006;18(3):145-148. (Pubitemid 44576434)
28. Nutt DJ, Fone K, Asherson P, et al. Evidence-based guidelines for management of attention-deficit/hyperactivity disorder in adolescents in transition to adult services and in adults: recommendations from the British Association for Psychopharmacology. J Psychopharmacol. 2007;21(1):10-41. (Pubitemid 46012081)
29. Stockl KM, Hughes TE, Jarrar MA, Secnik K, Perwien AR. Physician perceptions of the use of medications for attention deficit hyperactivity disorder. J Manag Care Pharm. 2003;9(5):416-423.
30. Safren SA. Cognitive-behavioral approaches to ADHD treatment in adulthood. J Clin Psychiatry. 2006;67 Suppl 8:46-50. (Pubitemid 44385606)
31. Rostain AL, Ramsay JR. A combined treatment approach for adults with ADHD - results of an open study of 43 patients. J Att Dis. 2006;10(2):150-159.
32. Pliszka S; AACAP Work Group on Quality Issues. Practice parameter for the assessment and treatment of children and adolescents with attention-deficit/ hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2007;46(7):894-921.
33. Greenhill LL, Pliszka S, Dulcan MK, et al. American Academy of Child and Adolescent Psychiatry. Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry. 2001;41(2 Suppl):26S-49S.
34. Wilens TE, Faraone SV, Biederman J, Gunawardene S. Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics. 2003;111(1):179-185. (Pubitemid 36071051)
35. Cox DJ, Merkel RL, Moore M, Thorndike F, Muller C, Kovatchev B. Relative benefits of stimulant therapy with OROS methylphenidate versus mixed amphetamine salts extended release in improving the driving performance of adolescent drivers with attention-deficit/hyperactivity disorder. Pediatrics. 2006;118(3):e704-e710. (Pubitemid 46089997)
36. Food and Drug Administration: Alert for healthcare professionals: Pemoline tablets and chewable tablets (marketed as Cylert). Food and Drug Administration Web site. Available from: www.fda.gov/cder/drug/InfoSheets/HCP/ pemolineHCP.htm. Accessed June 16, 2009.
37. Spencer T, Biederman J, Wilens T, et al. Efficacy of a mixed amphetamine salts compound in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2001;58(8):775-782. (Pubitemid 32717803)
38. Spencer T, Biederman J, Wilens T, et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005;57(5):456-463. (Pubitemid 40311979)
39. Weisler RH, Biederman J, Spencer TJ, et al. Mixed amphetamine salts extended-release in the treatment of adult ADHD: a randomized, controlled trial. CNS Spectr. 2006;11(8):625-639. (Pubitemid 44253518)
40. Spencer T, Wilens T, Biederman, Faraone S, Ablon S, Lapey K. A double - blind, crossover comparison of methylphenidate and placebo in adults with childhood onset attention - deficit hyperactivity disorder. Arch Gen Psychiatry. 1995;52:434-443.
41. Adler LA, Goodman DW, Kollins SH, et al. Double-blind, placebo-controlled study of the efficacy and safety of lisdexamfetamine dimesylate in adults with attention-deficit/hyperactivity disorder. J Clin Psychiatry. 2008;69(9):1364-1373.
42. Michelson D, Adler L, Spencer T, et al. Atomoxetine in adults with ADHD: two randomized, placebo-controlled studies. Biol Psychiatry. 2003;53(2):112-120. (Pubitemid 36126473)
43. Adler LA, Spencer TJ, Williams DW, Moore RJ, Michelson D. Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD:final report of a 4-year study. J Atten Disord. 2008;12(3):248-253.
44. Van Brunt DL, Johnston JA, Ye W, et al. Factors associated with initiation with atomoxetine versus stimulants in the treatment of adults with ADHD: retrospective analysis of administrative claims data. J Manag Care Pharm. 2006;12(3):230-238. (Pubitemid 47400612)
45. Wilens TE, Spencer TJ, Biederman J. A review of the pharmacotherapy of adults with attention-deficit/hyperactivity disorder. J Atten Disord. 2002;5(4):189-202. (Pubitemid 44844205)
46. Higgins ES. J A comparative analysis of antidepressants and stimulants for the treatment of adults with attention-deficit hyperactivity disorder. J Fam Pract. 1999;48(1):15-20.
47. Verbeeck W, Tuinier S, Bekkering GE. Antidepressants in the treatment of adult attention-deficit hyperactivity disorder: a systematic review. Adv Ther. 2009;26(2):170-184.
48. Connor DF, Fletcher KE, Swanson JM. A meta-analysis of clonidine for symptoms of attention-deficit hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 1999;38(12):1551-1559.
49. Lindsay SE, Gudelsky GA, Heaton PC. Use of modafinil for the treatment of attention deficit/hyperactivity disorder. Ann Pharmacother. 2006;40(10):1829-1833. (Pubitemid 44544881)
50. Elia J, Borcherding BG, Potter WZ, Mefford IN, Rapoport JL, Keysor CS. Stimulant drug treatment of hyperactivity: biochemical correlates. Clin Pharmacol Ther. 1990;48(1):57-66. (Pubitemid 20236203)
51. Krause J. SPECT and PET of the dopamine transporter in attention-deficit/hyperactivity disorder. Expert Rev Neurother. 2008;8(4):611-625. (Pubitemid 351551013)
52. Krause KH, Dresel SH, Krause J, Kung HF, Tatsch K. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett. 2000;285(2):107-110. (Pubitemid 30227631)
53. Faraone SV, Spencer T, Aleardi M, Pagano C, Biederman J. Meta-analysis of the efficacy of methylphenidate for treating adult attention-deficit/ hyperactivity disorder. J Clin Psychopharmacol. 2004;24(1):24-29. (Pubitemid 38134162)
54. Lutton ME, Leach L, Triezenberg D. Clinical inquiries. Does stimulant therapy help adult ADHD? J Fam Pract. 2003;52(11):888-889, 892.
55. Medori R, Ramos-Quiroga JA, Casas M, Kooij JJ, et al. A randomized, placebo-controlled trial of three fixed dosages of prolonged-release OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2008;63(10):981-989.
56. Jain U, Hechtman L, Weiss M, et al. Efficacy of a novel biphasic controlled-release methylphenidate formula in adults with attention-deficit/ hyperactivity disorder: results of a double-blind placebo-controlled crossover study. J Clin Psychiatry. 2007;68(2):268-277. (Pubitemid 46362649)
57. Reimherr FW, Williams ED, Strong RE, Mestas R, Soni P, Marchant BK. A double-blind, placebo-controlled, crossover study of osmotic release oral system methylphenidate in adults with ADHD with assessment of oppositional and emotional dimensions of the disorder. J Clin Psychiatry. 2007;68(1):93-101. (Pubitemid 46220130)
58. Biederman J, Mick E, Surman C, et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006;59(9):829-835.
59. Biederman J, Mick EO, Surman C, et al. Comparative acute efficacy and tolerability of OROS and immediate release formulations of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. BMC Psychiatry. 2007;4(7):49. (Pubitemid 350111687)
60. Fallu A, Richard C, Prinzo R, Binder C. Does OROS-methylphenidate improve core symptoms and deficits in executive function? Results of an open-label trial in adults with attention deficit hyperactivity disorder. Curr Med Res Opin. 2006;22(12):2557-2566. (Pubitemid 46048371)
61. Rösler M, Fischer R, Ammer R, Ose C, Retz W. A randomised, placebo-controlled, 24-week, study of low-dose extended-release methylphenidate in adults with attention-deficit/hyperactivity disorder. Eur Arch Psychiatry Clin Neurosci. 2009;259(2):120-129.
62. Reinhardt MC, Benetti L, Victor MM, Grevet EH, et al. Is age-at-onset criterion relevant for the response to methylphenidate in attention-deficit/ hyperactivity disorder? J Clin Psychiatry. 2007;68(7):1109-1116. (Pubitemid 47340334)
63. Gorman EB, Klorman R, Thatcher JE, Borgstedt AD. Effects of methylphenidate on subtypes of attention-deficit/hyperactivity disorder. J Am Acad Child Adolesc Psychiatry. 2006;45(7):808-816. (Pubitemid 43932907)
64. Biederman J, Monuteaux MC, Spencer T, Wilens TE, Macpherson HA, Faraone SV. Stimulant therapy and risk for subsequent substance use disorders in male adults with ADHD: a naturalistic controlled 10-year follow-up study. Am J Psychiatry. 2008;165(5):597-603. (Pubitemid 351705336)
65. Levin FR, Evans SM, Brooks DJ, Garawi F. Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend. 2007;87(1):20-29. (Pubitemid 46074379)
66. Peterson K, McDonagh MS, Fu R. Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis. Psychopharmacology (Berl). 2008;197(1):1-11.
67. Kuperman S, Perry PJ, Gaffney GR, et al. Bupropion SR vs methylphenidate vs placebo for attention deficit hyperactivity disorder in adults. Ann Clin Psychiatry. 2001;13(3):129-134. (Pubitemid 34020146)
68. Levin FR, Evans SM, Brooks DJ, Kalbag AS, Garawi F, Nunes EV. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend. 2006;81(2):137-148. (Pubitemid 41821797)
69. Palumbo DR, Sallee FR, Pelham WE Jr, Bukstein OG, Daviss WB, McDermott MP. Clonidine for attention-deficit/hyperactivity disorder: I. Efficacy and tolerability outcomes. J Am Acad Child Adolesc Psychiatry. 2008;47(2):180-218.
70. Low K, Gendaszek AE. Illicit use of psychostimulants among college students: a preliminary study. Psychol Health Med. 2002;7:283-287. (Pubitemid 34885841)
71. Weisler RH, Biederman J, Spencer TJ, Wilens TE. Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr. 2005;10(12 Suppl 20):35-43. (Pubitemid 43010496)
72. Wilens TE, Hammerness PG, Biederman J, et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/ hyperactivity disorder. J Clin Psychiatry. 2005;66(2):253-259. (Pubitemid 40314334)
73. Vetter VL, Elia J, Erickson C, et al. Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation. 2008;117(18):2407-2423. (Pubitemid 351653546)
74. Center for Drug Evaluation and Research. Food and Drug Administration Web site. Available from: www.accessdata.fda.gov/scripts/cder/drugsatfda. Accessed June 16, 2009.
75. Briggs, GG, Freman RK, Yaffe SJ. Drugs in Pregnancy and Lactation, 7th edition. Lippincott Williams & Wilkins; 2005. p. 1056-1057.
76. Golub M, Costa L, Crofton K, et al. NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of methylphenidate. Birth Defects Res B Dev Reprod Toxicol. 2005;74(4):300-381. (Pubitemid 41267328)
77. Einarson A. Abrupt discontinuation of psychotropic drugs following confirmation of pregnancy: a risky practice. J Obstet Gynaecol Can. 2005;27(11):1019-1022.
78. King S, Griffin S, Hodges Z, et al. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technol Assess. 2006;10(23):iii-iv, xiii-146. (Pubitemid 44317375)
79. Marchetti A, Magar R, Lau H, et al. Pharmacotherapies for attention-deficit/hyperactivity disorder: expected-cost analysis. Clin Ther. 2001;23(11):1904-1921. (Pubitemid 33121978)
80. Wu EQ, Birnbaum HG, Zhang HF, Ivanova JI, Yang E, Mallet D. Health care costs of adults treated for attention-deficit/hyperactivity disorder who received alternative drug therapies. J Manag Care Pharm. 2007;13(7):561-569. (Pubitemid 47605350)